Evidence map›Paper›PMID 35892430›Full record

ArticleBrain sciences2022

A Novel Necroptosis-Related Prognostic Signature of Glioblastoma Based on Transcriptomics Analysis and Single Cell Sequencing Analysis.

Yiwen Wu, Yi Huang, Chenhui Zhou, Haifeng Wang, Zhepei Wang, Jiawei Wu, Sheng Nie, Xinpeng Deng, Jie Sun, Xiang Gao

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yiwen WuDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.ORCID 0000-0003-0774-4806
Yi HuangDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.ORCID 0000-0003-3598-9747
Chenhui ZhouDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Haifeng WangDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Zhepei WangDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Jiawei WuDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Sheng NieDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Xinpeng DengDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Jie SunDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.
Xiang GaoDepartment of Neurosurgery, Ningbo First Hospital, Zhejiang University School of Medicine, Ningbo 315010, China.ORCID 0000-0002-6844-9651
Ningbo First Hospital · CN

Funding

Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province 2022E10026Medicine and health science and technology projects of Zhejiang province 2022KY305, 2022KY322National Natural Science Foundation of China 82101354Ningbo Health Branding Subject Fund PPXK2018-04Zhejiang Provincial Natural Science Foundation of China LY22H090001
6 · The paper itself

Abstract

Background: Glioblastoma (GBM) is the most common and deadly brain tumor. The clinical significance of necroptosis (NCPS) genes in GBM is unclear. The goal of this study is to reveal the potential prognostic NCPS genes associated with GBM, elucidate their functions, and establish an effective prognostic model for GBM patients. Methods: Firstly, the NCPS genes in GBM were identified by single-cell analysis of the GSE182109 dataset in the GEO database and weighted co-expression network analysis (WGCNA) of The Cancer Genome Atlas (TCGA) data. Three machine learning algorithms (Lasso, SVM-RFE, Boruta) combined with COX regression were used to build prognostic models. The subsequent analysis included survival, immune microenvironments, and mutations. Finally, the clinical significance of NCPS in GBM was explored by constructing nomograms. Results: We constructed a GBM prognostic model composed of NCPS-related genes, including CTSD, AP1S1, YWHAG, and IER3, which were validated to have good performance. According to the above prognostic model, GBM patients in the TCGA and CGGA groups could be divided into two groups according to NCPS, with significant differences in survival analysis between the two groups and a markedly worse prognostic status in the high NCPS group (p < 0.001). In addition, the high NCPS group had higher levels of immune checkpoint-related gene expression, suggesting that they may be more likely to benefit from immunotherapy. Conclusions: Four genes (CTSD, AP1S1, YWHAG, and IER3) were screened through three machine learning algorithms to construct a prognostic model for GBM. These key and novel diagnostic markers may become new targets for diagnosing and treating patients with GBM.

Indexed as

glioblastomaimmune microenvironmentsmachine learning algorithmsnecroptosissingle-cell analysis

Identifiers

PMID35892430
PMCPMC9460316
OpenAlexW4288039537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.